Physician profile
Jasdeep Sidhu
NPI 1760935910
$12,305.46
in general payments reported to CMS, 2019-2025
68 companies · $3,183 in 2025
The $3,183 reported for 2025 was more than what 75% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.20 · 2020: $432 · 2021: $2,398 · 2022: $1,669 · 2023: $1,950 · 2024: $2,657 · 2025: $3,183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,461 · Education: $328.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,461.16 |
| Education | $327.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $991.15 | 2024-2025 | |
| Amgen INC. | $953.67 | 2020-2023 | Lumakras, Kyprolis, Blincyto |
| Genzyme Corporation | $652.79 | 2021-2025 | |
| Daiichi Sankyo INC. | $645.61 | 2021-2025 | Enhertu, Datroway, Injectafer |
| Incyte Corporation | $642.13 | 2020-2025 | Jakafi, Monjuvi, Pemazyre |
| Astrazeneca Pharmaceuticals Lp | $627.52 | 2021-2025 | Tagrisso, Lynparza, Imfinzi |
| Celgene Corporation | $602.91 | 2022-2025 | Reblozyl, Pomalyst |
| Beigene USA, INC. | $500.97 | 2021-2024 | Brukinsa |
| Seagen INC. | $496.08 | 2021-2023 | Padcev, Adcetris |
| E.R. Squibb & Sons, L.L.C. | $489.54 | 2020-2025 | Opdivo, Opdualag |
| Janssen Biotech, INC. | $440.24 | 2023-2025 | Tecvayli, Darzalex, Erleada |
| Abbvie INC. | $412.22 | 2021-2025 | Venclexta |
| Pfizer INC. | $359.67 | 2021-2025 | |
| Gilead Sciences, INC. | $318.73 | 2022-2025 | Trodelvy |
| Merck Sharp & Dohme LLC | $300.75 | 2020-2025 | Keytruda, Lynparza, Keytruda Qlex |
Show all 68 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $282.50 | 2020-2023 | Imbruvica |
| Eisai INC. | $282.47 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $243.97 | 2019-2025 | |
| Rigel Pharmaceuticals, INC. | $180.25 | 2021-2024 | Tavalisse, Rezlidhia |
| Regeneron Healthcare Solutions, INC. | $178.24 | 2021-2025 | Libtayo |
| Emd Serono, INC. | $175.33 | 2020-2022 | |
| Sobi, INC | $156.76 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $150.33 | 2023-2025 | Fruzaqla, Ninlaro, Iclusig |
| Ipsen Biopharmaceuticals, INC | $139.99 | 2021-2025 | Onivyde, Tazverik |
| Bayer Healthcare Pharmaceuticals INC. | $132.95 | 2022-2025 | |
| Tempus Ai, INC | $115.86 | 2024 | |
| Lilly USA, LLC | $113.12 | 2024-2025 | Verzenio, Jaypirca, Retevmo |
| Adc Therapeutics America, INC. | $111.55 | 2023 | |
| Mirati Therapeutics, INC. | $90.55 | 2023-2024 | Krazati |
| Alexion Pharmaceuticals, INC. | $89.76 | 2023-2025 | Ultomiris |
| Tersera Therapeutics LLC | $86.58 | 2023-2025 | Zoladex, Xermelo |
| Pharmaessentia USA Corporation | $81.95 | 2024-2025 | Besremi |
| Puma Biotechnology, INC. | $66.30 | 2023-2025 | Nerlynx |
| Sun Pharmaceutical Industries INC. | $65.32 | 2023-2024 | Yonsa, Odomzo |
| Astellas Pharma US INC | $56.32 | 2024-2025 | Xtandi |
| Pharmacosmos Therapeutics INC. | $50.88 | 2022-2025 | Monoferric |
| Coherus Oncology, INC. | $47.99 | 2022-2023 | |
| Deciphera Pharmaceuticals INC. | $47.48 | 2021-2024 | Qinlock |
| Kyowa Kirin, INC. | $47.11 | 2023-2025 | Poteligeo |
| Agios Pharmaceuticals, INC. | $46.26 | 2024-2025 | Pyrukynd |
| Karyopharm Therapeutics INC. | $45.63 | 2023-2025 | Xpovio |
| Acrotech Biopharma INC. | $44.46 | 2023-2025 | Beleodaq |
| Genmab U.S., INC. | $41.53 | 2024 | Tivdak, Epkinly |
| Syndax Pharmaceuticals, INC. | $41.16 | 2025 | Revuforj |
| Stemline Therapeutics INC. | $41.03 | 2024-2025 | Orserdu |
| Geron Corporation | $40.02 | 2025 | Rytelo |
| Kite Pharma, INC. | $39.54 | 2022-2025 | Yescarta |
| Accord Healthcare, INC. | $38.99 | 2025 | |
| Beone Medicines USA, INC. | $37.28 | 2025 | Tevimbra |
| Blueprint Medicines Corporation | $35.66 | 2023-2025 | Ayvakit |
| Genentech USA, INC. | $35.54 | 2025 | Tecentriq |
| Sumitomo Pharma America, INC. | $35.41 | 2023-2025 | Orgovyx |
| Springworks Therapeutics, INC. | $34.00 | 2024-2025 | Gomekli, Ogsiveo |
| Alnylam Pharmaceuticals INC. | $33.50 | 2024-2025 | Givlaari |
| Azurity Pharmaceuticals, INC. | $32.37 | 2024-2025 | Vivimusta, Danziten |
| Jazz Pharmaceuticals INC. | $28.77 | 2024 | |
| Aveo Pharmaceuticals, INC. | $28.62 | 2024-2025 | |
| Siemens Medical Solutions USA, INC. | $26.45 | 2024 | Cios Spin |
| Iovance Biotherapeutics, INC. | $24.40 | 2025 | Amtagvi |
| Fresenius Kabi USA, LLC | $23.67 | 2024 | Stimufend |
| Cti Biopharma Corp. | $19.25 | 2022 | |
| Glaxosmithkline, LLC. | $16.83 | 2023 | Ojjaara |
| Cumberland Pharmaceuticals, INC. | $16.62 | 2024 | Sancuso |
| Apellis Pharmaceuticals, INC. | $15.70 | 2022 | |
| Secura Bio, INC. | $14.52 | 2024 | Copiktra |
| Exelixis INC. | $14.21 | 2024 | Cabometyx |
| Caris Mpi, INC. | $13.95 | 2025 | Mi Cancer Seek |
| Immunomedics, INC. | $12.55 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jasdeep Sidhu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.